Abstract

The role of antibodies in the pathogenesis of chronic rejection is increasingly acknowledged. In contrast, whether B-cell clusters, which have been recently identified in chronically rejected allografts, actively participate in the process or are only an epiphenomenon remain a matter of debate. Integrating recently published data, we put forward explanations that reconcile the conflicting conclusions of experimental and biopsy-based studies. Finally, we propose a unified model in which B-cell clusters as part of intragraft tertiary lymphoid tissue can play deleterious or regulatory roles and therefore actively modulate the kinetics of chronic rejection.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call